HBVAXPRO 40, Injektionssuspension

7680005450012 CH-545 Injektionssuspension

Associated product:

HBVAXPRO sol inj 40 mcg dialyse flac 1 ml
HBVAXPRO 40, Injektionssuspension
HBVAXPRO 40, Injektionssuspension
HBVAXPRO 40, Injektionssuspension
1 / 3
google

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Injektionssuspension
Galenic group
Injektion/Infusion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
10/12/2021
Summary of Product Characteristics
Français
10/12/2021
Summary of Product Characteristics
Italien
10/12/2021

Detailed composition

Substance Quantity Type Category
(N/A)
40.0 UG Substance Wirkstoff (Principe actif)
(N/A)
0.5 MG Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
3.5 MG Substance HBESI

Reimbursement information

Public price
CHF 62.20
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 15/03/1997

Authorization holder

MSD Merck Sharp & Dohme AG

6005 Luzern

Authorization information

Swissmedic authorization number
545
Drug name
HBVAXPRO 40, Injektionssuspension
Galenic form
SUPA
ATC Code
J07BC01
Authorization status
Z
Dispensing category
B
First authorization
18/04/1988
Authorization expiration date
31/12/9999
IT Number
08.08.
Domain
Human medicine
Field of application
aktive Immunisierung gegen Hepatitis B, bei Dialyse- und Prädialysepatienten, ab dem vollendeten 19. Lebensjahr

Package details

Description (FR)
HBVAXPRO susp inj 40 µg 1 pce
Description (DE)
HBVAXPRO Inj Susp 40 µg 1 Stk
Market launch
18/04/1988
Narcotic (BTM)
No

Application methods

IMU